A PYMNTS Company

UK Fines Drug Firms For NHS 10,000% Price Hikes

By  |  July 15, 2021

Britain’s competition regulator has fined more than 10 drug firms a record combined 260 million pounds ($360 million) for overcharging the National Health Service (NHS) for a steroid which rose from 70p to 88 pounds a pack in under eight years.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Competition and Markets Authority (CMA) said on Thursday that the breaches meant the NHS paid over 10,000% more for single packs of 10 mg and 20 mg hydrocortisone tablets in 2016 than they were paying in 2008.

    Hydrocortisone is used to treat conditions where adrenal glands do not make sufficient hormones, including the life-threatening Addison’s disease.

    The CMA said companies including Actavis, and its former parent and now Abbvie-owned Allergan, broke competition rules.

    The companies engaged in practices including buying potential rivals to keep their versions off the market, increasing the price of hydrocortisone as sole providers, and continued to pay off the competition over the years, the CMA said.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.